These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8332148)

  • 1. Mexiletine for treatment of spasticity due to neurological disorders.
    Jimi T; Wakayama Y
    Muscle Nerve; 1993 Aug; 16(8):885. PubMed ID: 8332148
    [No Abstract]   [Full Text] [Related]  

  • 2. Principles of pharmaceutical management of spastic hypertonia.
    Elovic E
    Phys Med Rehabil Clin N Am; 2001 Nov; 12(4):793-816, vii. PubMed ID: 11727721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Meningitis due to Escherichia coli as a delayed complication of intrathecal baclofen pump systems].
    Pérez-Quesada S; Martín-Estefanía C; Martí-Martínez S; Turpín-Fenoll L
    Rev Neurol; 2006 Jun 16-30; 42(12):764-6. PubMed ID: 16775804
    [No Abstract]   [Full Text] [Related]  

  • 4. Botulinum toxin for the management of adult patients with upper motor neuron syndrome.
    Esquenazi A; Mayer NH; Elia AE; Albanese A
    Toxicon; 2009 Oct; 54(5):634-8. PubMed ID: 19470335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.
    Bedlack RS; Pastula DM; Hawes J; Heydt D
    Amyotroph Lateral Scler; 2009 Aug; 10(4):210-5. PubMed ID: 18821142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common patterns of clinical motor dysfunction.
    Mayer NH; Esquenazi A; Childers MK
    Muscle Nerve Suppl; 1997; 6():S21-35. PubMed ID: 9826981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of spasticity].
    Ben Smaïl D; Kiefer C; Bussel B
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):190-8. PubMed ID: 12746693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal baclofen bolus complicated by deep vein thrombosis and pulmonary embolism. A case report.
    Carda S; Cazzaniga M; Taiana C; Pozzi R
    Eur J Phys Rehabil Med; 2008 Mar; 44(1):87-8. PubMed ID: 18385632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion.
    Mayer NH
    Muscle Nerve Suppl; 1997; 6():S1-13. PubMed ID: 9826979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrater reliability of the Modified Modified Ashworth Scale (MMAS) for patients with wrist flexor muscle spasticity.
    Naghdi S; Ansari NN; Azarnia S; Kazemnejad A
    Physiother Theory Pract; 2008; 24(5):372-9. PubMed ID: 18821443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spasticity. Physical therapy, preventive measures and treatment].
    Gay S; Egon G
    Ann Fr Anesth Reanim; 2005 Jun; 24(6):663-6. PubMed ID: 15950113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical overview of treatment decisions in the management of spasticity.
    Gormley ME; O'Brien CF; Yablon SA
    Muscle Nerve Suppl; 1997; 6():S14-20. PubMed ID: 9826980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary management of motor neurone disease.
    Lau FS; Brennan FP; Gardiner MD
    Aust J Gen Pract; 2018 Sep; 47(9):593-597. PubMed ID: 30244551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum treatment for post-stroke spasticity: low dose regime.
    Viriyavejakul A; Vachalathiti R; Poungvarin N
    J Med Assoc Thai; 1998 Jun; 81(6):413-22. PubMed ID: 9676073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective peripheral neurolysis using high frequency ultrasound imaging: a novel approach in the treatment of spasticity.
    Kaymak B; Kara M; Gürçay E; Aydin G; Özçakar L
    Eur J Phys Rehabil Med; 2019 Aug; 55(4):522-525. PubMed ID: 29898589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
    Slawek J; Bogucki A; Reclawowicz D
    Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Symptomatic treatments in amyotrophic lateral sclerosis].
    Clavelou P; Guy N
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S228-4S234. PubMed ID: 17128116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of botulinum toxin in spasticity and headaches: a common key?
    Sandrini G
    Funct Neurol; 2008; 23(2):61. PubMed ID: 18671904
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).
    Simpson DM; Gracies JM; Graham K; Hallett M; Miyasaki J; Naumann M; Russman B; Simpson L; So Y
    Neurology; 2009 Sep; 73(9):736-7; author reply 737-8. PubMed ID: 19728407
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of mexiletine on excitability properties of human median motor axons.
    Kuwabara S; Misawa S; Tamura N; Kanai K; Hiraga A; Ogawara K; Nakata M; Hattori T
    Clin Neurophysiol; 2005 Feb; 116(2):284-9. PubMed ID: 15661106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.